Key Takeaways Consistent Profitability — Q3 2025 net revenue reached $10.5M with $0.8M net income, marking BioStem’s seventh consecutive quarter of positive adjusted EBITDA. Clinical & Regulatory Progress — Positive BioREtain® trial results published in the International Journal of Tissue Repair; FDA reinspection completed with no observations. Strategic Expansion & Partnerships — BioStem secured land for its new Boca Raton HQ, partnered with a Service-Disabled Veteran-Owned Small...





















